TP53 and neoplasm: Despite the efficacy of venetoclax toward TP53-deleted/mutated malignant cells has been repeatedly confirmed by many independent researchers, the most recent data brought evidence that the tumor suppressor function of p53 is nevertheless requisite for sustaining durable responses to venetoclax [88,89].